ATR kinase inhibitors induce mitochondrial fission in CD8+ T cells and impair immune memory in vivo
Vendetti, F. P.; Sclafani, C. R.; Zhang, Y.; Pandya, P.; Mowery, Y. M.; Kim, S. H.; Cumberland, R. L.; Ganakammal, S. R.; Conrads, T. P.; Calderon, M. J.; Watkins, S. C.; Van Houten, B.; Clump, A.; Ferris, R. L.; Beumer, J. H.; Delgoffe, G. M.; Kane, L. P.; Bakkenist, C. J.
Show abstract
The DNA damage response kinase ATR restrains CDK1 activity during S and G2 phases of the cell cycle, confining CDK1-driven processes to mitosis. ATR kinase inhibitors were originally developed to potentiate chemotherapy-induced DNA damage at stalled replication forks and to disrupt DNA damage-induced cell cycle checkpoints. Recent evidence, however, reveals that these inhibitors also disrupt cell cycle organization in cells that have not sustained any DNA damage. We show that ATR kinase inhibitors potently trigger unscheduled mitochondrial fission, causing loss of mitochondrial mass in actively dividing CD8+ T cells that persists in memory CD8+ T cells. Moreover, ATR inhibition during the peak of CD8+ T cell expansion in a mouse model of LCMV Armstrong infection impairs the formation of immune memory. These findings carry significant clinical implications. ATR kinase inhibitors are currently being evaluated in clinical trials in combination with chemotherapy, radiation, and immune checkpoint inhibitors in patients where anti-tumor immune responses are recognized as a determinant of durable response. Our results identify an unexpected consequence of ATR inhibition that disrupts cellular metabolism with broad implications for both preclinical research and clinical application.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.